Exact Mass: 747.5050074
Exact Mass Matches: 747.5050074
Found 417 metabolites which its exact mass value is equals to given mass value 747.5050074,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Clarithromycin
Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration. J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01F - Macrolides, lincosamides and streptogramins > J01FA - Macrolides D004791 - Enzyme Inhibitors > D065607 - Cytochrome P-450 Enzyme Inhibitors > D065692 - Cytochrome P-450 CYP3A Inhibitors COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D004791 - Enzyme Inhibitors > D011500 - Protein Synthesis Inhibitors D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents C784 - Protein Synthesis Inhibitor > C261 - Macrolide Antibiotic CONFIDENCE standard compound; EAWAG_UCHEM_ID 191 EAWAG_UCHEM_ID 191; CONFIDENCE standard compound C254 - Anti-Infective Agent > C258 - Antibiotic CONFIDENCE standard compound; INTERNAL_ID 1053 Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Spinetoram
D010575 - Pesticides > D007306 - Insecticides D016573 - Agrochemicals
PE(P-16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
C43H74NO7P (747.5202623999999)
PE(P-16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) belongs to a class of glycerophospholipids in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the sn-1 and sn-2 positions. Fatty acids containing 16, 18, and 20 carbons are the most common (LipidMAPS). PE(P-16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) is a phosphatidylethanolamine (PE or GPEtn) and consists of one chain of plasmalogen 16:0 at the C-1 position and one chain of docosahexaenoic acid at the C-2 position. The plasmalogen 18:0 moiety is derived from animal fats, liver, and kidney, while the arachidonic acid moiety is derived from animal fats and eggs. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signalling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodelling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4, and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine, and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0, and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. A class of glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the SN-1 and SN-2 positions. fatty acids containing 16, 18 and 20 carbons are the most common. (LipidMAPS)
PE(20:5(5Z,8Z,11Z,14Z,17Z)/P-18:1(11Z))
C43H74NO7P (747.5202623999999)
PE(20:5(5Z,8Z,11Z,14Z,17Z)/P-18:1(11Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(20:5(5Z,8Z,11Z,14Z,17Z)/P-18:1(11Z)), in particular, consists of one chain of eicosapentaenoic acid at the C-1 position and one chain of plasmalogen 18:1n7 at the C-2 position. The eicosapentaenoic acid moiety is derived from fish oils, liver and kidney, while the plasmalogen 18:1n7 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PE(20:5(5Z,8Z,11Z,14Z,17Z)/P-18:1(11Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(20:5(5Z,8Z,11Z,14Z,17Z)/P-18:1(11Z)), in particular, consists of one chain of eicosapentaenoic acid at the C-1 position and one chain of plasmalogen 18:1n7 at the C-2 position. The eicosapentaenoic acid moiety is derived from fish oils, liver and kidney, while the plasmalogen 18:1n7 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PE(20:5(5Z,8Z,11Z,14Z,17Z)/P-18:1(9Z))
C43H74NO7P (747.5202623999999)
PE(20:5(5Z,8Z,11Z,14Z,17Z)/P-18:1(9Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(20:5(5Z,8Z,11Z,14Z,17Z)/P-18:1(9Z)), in particular, consists of one chain of eicosapentaenoic acid at the C-1 position and one chain of plasmalogen 18:1n9 at the C-2 position. The eicosapentaenoic acid moiety is derived from fish oils, liver and kidney, while the plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.
PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/P-16:0)
C43H74NO7P (747.5202623999999)
PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/P-16:0) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/P-16:0), in particular, consists of one chain of docosahexaenoic acid at the C-1 position and one chain of plasmalogen 16:0 at the C-2 position. The docosahexaenoic acid moiety is derived from fish oils, while the plasmalogen 16:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.
PE(P-18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
C43H74NO7P (747.5202623999999)
Phosphatidylethanolamines (cephalin, sometimes abbreviated PE) are a class of phospholipids found in biological membranes. They are synthesized by the addition of CDP-ethanolamine to diglycerides, releasing CMP. S-Adenosyl methionine can subsequently methylate the amine of phosphatidylethanolamines to yield phosphatidylcholines (Wikipedia). Cephalin is a phospholipid, which is a lipid derivative. It is not to be confused with the molecule of the same name that is an alkaloid constituent of Ipecac. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. A class of glycerophospholipids in which a phosphatidyl group is esterified to the hydroxyl group of ethanolamine. (ChEBI). Phosphatidylethanolamine is found in many foods, some of which are sunflower, lemon, common grape, and spinach.
PE(P-18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
C43H74NO7P (747.5202623999999)
PE(P-18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)), in particular, consists of one chain of plasmalogen 18:1n9 at the C-1 position and one chain of eicosapentaenoic acid at the C-2 position. The plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney, while the eicosapentaenoic acid moiety is derived from fish oils, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PE(P-18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)), in particular, consists of one chain of plasmalogen 18:1n9 at the C-1 position and one chain of eicosapentaenoic acid at the C-2 position. The plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney, while the eicosapentaenoic acid moiety is derived from fish oils, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PS(15:0/18:1(11Z))
PS(15:0/18:1(11Z)) is a phosphatidylserine. It is a glycerophospholipid in which a phosphorylserine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidylserines can have many different combinations of fatty acids of varying lengths and saturation attached to the C-1 and C-2 atoms. PS(15:0/18:1(11Z)), in particular, consists of one pentadecanoyl chain to the C-1 atom, and one 11Z-octadecenoyl to the C-2 atom. Phosphatidylserine or 1,2-diacyl-sn-glycero-3-phospho-L-serine is distributed widely among animals, plants and microorganisms. Phosphatidylserine is an acidic (anionic) phospholipid with three ionizable groups, i.e. the phosphate moiety, the amino group and the carboxyl function. As with other acidic lipids, it exists in nature in salt form, but it has a high propensity to chelate to calcium via the charged oxygen atoms of both the carboxyl and phosphate moieties, modifying the conformation of the polar head group. This interaction may be of considerable relevance to the biological function of phosphatidylserine. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Phosphatidylserines typically carry a net charge of -1 at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PS biosynthesis involves an exchange reaction of serine for ethanolamine in PE.
PS(15:0/18:1(9Z))
PS(15:0/18:1(9Z)) is a phosphatidylserine. It is a glycerophospholipid in which a phosphorylserine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidylserines can have many different combinations of fatty acids of varying lengths and saturation attached to the C-1 and C-2 atoms. PS(15:0/18:1(9Z)), in particular, consists of one pentadecanoyl chain to the C-1 atom, and one 9Z-octadecenoyl to the C-2 atom. Phosphatidylserine or 1,2-diacyl-sn-glycero-3-phospho-L-serine is distributed widely among animals, plants and microorganisms. Phosphatidylserine is an acidic (anionic) phospholipid with three ionizable groups, i.e. the phosphate moiety, the amino group and the carboxyl function. As with other acidic lipids, it exists in nature in salt form, but it has a high propensity to chelate to calcium via the charged oxygen atoms of both the carboxyl and phosphate moieties, modifying the conformation of the polar head group. This interaction may be of considerable relevance to the biological function of phosphatidylserine. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Phosphatidylserines typically carry a net charge of -1 at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PS biosynthesis involves an exchange reaction of serine for ethanolamine in PE.
PS(18:1(11Z)/15:0)
PS(18:1(11Z)/15:0) is a phosphatidylserine. It is a glycerophospholipid in which a phosphorylserine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidylserines can have many different combinations of fatty acids of varying lengths and saturation attached to the C-1 and C-2 positions. PS(18:1(11Z)/15:0), in particular, consists of one chain of cis-vaccenic acid at the C-1 position and one chain of pentadecanoic acid at the C-2 position. Phosphatidylserine or 1,2-diacyl-sn-glycero-3-phospho-L-serine is distributed widely among animals, plants, and microorganisms. Phosphatidylserine is an acidic (anionic) phospholipid with three ionizable groups (i.e. the phosphate moiety, the amino group and the carboxyl group). As with other acidic lipids, it exists in nature in salt form, but it has a high propensity to chelate calcium via the charged oxygen atoms of both the carboxyl and phosphate moieties, modifying the conformation of the polar head group. This interaction may be of considerable relevance to the biological function of phosphatidylserine. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Phosphatidylserines typically carry a net charge of -1 at physiological pH. They mostly have a palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PS biosynthesis involves an exchange reaction of serine for ethanolamine in PE.
PS(18:1(9Z)/15:0)
PS(18:1(9Z)/15:0) is a phosphatidylserine. It is a glycerophospholipid in which a phosphorylserine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidylserines can have many different combinations of fatty acids of varying lengths and saturation attached to the C-1 and C-2 positions. PS(18:1(9Z)/15:0), in particular, consists of one chain of oleic acid at the C-1 position and one chain of pentadecanoic acid at the C-2 position. Phosphatidylserine or 1,2-diacyl-sn-glycero-3-phospho-L-serine is distributed widely among animals, plants, and microorganisms. Phosphatidylserine is an acidic (anionic) phospholipid with three ionizable groups (i.e. the phosphate moiety, the amino group and the carboxyl group). As with other acidic lipids, it exists in nature in salt form, but it has a high propensity to chelate calcium via the charged oxygen atoms of both the carboxyl and phosphate moieties, modifying the conformation of the polar head group. This interaction may be of considerable relevance to the biological function of phosphatidylserine. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Phosphatidylserines typically carry a net charge of -1 at physiological pH. They mostly have a palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PS biosynthesis involves an exchange reaction of serine for ethanolamine in PE.
PE-NMe(14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
PE-NMe(14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) is a monomethylphosphatidylethanolamine. It is a glycerophospholipid, and it is formed by sequential methylation of phosphatidylethanolamine as part of a mechanism for biosynthesis of phosphatidylcholine. Monomethylphosphatidylethanolamines are usually found at trace levels in animal or plant tissues. They can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PE-NMe(14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)), in particular, consists of one chain of myristoleic acid at the C-1 position and one chain of docosahexaenoic acid at the C-2 position. Fatty acids containing 16, 18 and 20 carbons are the most common. Phospholipids are ubiquitous in nature. They are key components of the cell lipid bilayer and are involved in metabolism and signaling.
PE-NMe(18:3(6Z,9Z,12Z)/18:4(6Z,9Z,12Z,15Z))
PE-NMe(18:3(6Z,9Z,12Z)/18:4(6Z,9Z,12Z,15Z)) is a monomethylphosphatidylethanolamine. It is a glycerophospholipid, and it is formed by sequential methylation of phosphatidylethanolamine as part of a mechanism for biosynthesis of phosphatidylcholine. Monomethylphosphatidylethanolamines are usually found at trace levels in animal or plant tissues. They can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PE-NMe(18:3(6Z,9Z,12Z)/18:4(6Z,9Z,12Z,15Z)), in particular, consists of one chain of gamma-linolenic acid at the C-1 position and one chain of stearidonic acid at the C-2 position. Fatty acids containing 16, 18 and 20 carbons are the most common. Phospholipids are ubiquitous in nature. They are key components of the cell lipid bilayer and are involved in metabolism and signaling.
PE-NMe(18:3(9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))
PE-NMe(18:3(9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z)) is a monomethylphosphatidylethanolamine. It is a glycerophospholipid, and it is formed by sequential methylation of phosphatidylethanolamine as part of a mechanism for biosynthesis of phosphatidylcholine. Monomethylphosphatidylethanolamines are usually found at trace levels in animal or plant tissues. They can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PE-NMe(18:3(9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z)), in particular, consists of one chain of alpha-linolenic acid at the C-1 position and one chain of stearidonic acid at the C-2 position. Fatty acids containing 16, 18 and 20 carbons are the most common. Phospholipids are ubiquitous in nature. They are key components of the cell lipid bilayer and are involved in metabolism and signaling.
PE-NMe(18:4(6Z,9Z,12Z,15Z)/18:3(6Z,9Z,12Z))
PE-NMe(18:4(6Z,9Z,12Z,15Z)/18:3(6Z,9Z,12Z)) is a monomethylphosphatidylethanolamine. It is a glycerophospholipid, and it is formed by sequential methylation of phosphatidylethanolamine as part of a mechanism for biosynthesis of phosphatidylcholine. Monomethylphosphatidylethanolamines are usually found at trace levels in animal or plant tissues. They can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PE-NMe(18:4(6Z,9Z,12Z,15Z)/18:3(6Z,9Z,12Z)), in particular, consists of one chain of stearidonic acid at the C-1 position and one chain of gamma-linolenic acid at the C-2 position. Fatty acids containing 16, 18 and 20 carbons are the most common. Phospholipids are ubiquitous in nature. They are key components of the cell lipid bilayer and are involved in metabolism and signaling.
PE-NMe(18:4(6Z,9Z,12Z,15Z)/18:3(9Z,12Z,15Z))
PE-NMe(18:4(6Z,9Z,12Z,15Z)/18:3(9Z,12Z,15Z)) is a monomethylphosphatidylethanolamine. It is a glycerophospholipid, and it is formed by sequential methylation of phosphatidylethanolamine as part of a mechanism for biosynthesis of phosphatidylcholine. Monomethylphosphatidylethanolamines are usually found at trace levels in animal or plant tissues. They can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PE-NMe(18:4(6Z,9Z,12Z,15Z)/18:3(9Z,12Z,15Z)), in particular, consists of one chain of stearidonic acid at the C-1 position and one chain of alpha-linolenic acid at the C-2 position. Fatty acids containing 16, 18 and 20 carbons are the most common. Phospholipids are ubiquitous in nature. They are key components of the cell lipid bilayer and are involved in metabolism and signaling.
PE-NMe(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/14:1(9Z))
PE-NMe(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/14:1(9Z)) is a monomethylphosphatidylethanolamine. It is a glycerophospholipid, and it is formed by sequential methylation of phosphatidylethanolamine as part of a mechanism for biosynthesis of phosphatidylcholine. Monomethylphosphatidylethanolamines are usually found at trace levels in animal or plant tissues. They can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PE-NMe(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/14:1(9Z)), in particular, consists of one chain of docosahexaenoic acid at the C-1 position and one chain of myristoleic acid at the C-2 position. Fatty acids containing 16, 18 and 20 carbons are the most common. Phospholipids are ubiquitous in nature. They are key components of the cell lipid bilayer and are involved in metabolism and signaling.
PS(O-20:0/14:1(9Z))
C40H78NO9P (747.5413907999999)
PE(15:0/5-iso PGF2VI)
PE(15:0/5-iso PGF2VI) is an oxidized phosphatidylethanolamine (PE). Oxidized phosphatidylethanolamines are glycerophospholipids in which a phosphorylethanolamine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylethanolamines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylethanolamines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PE(15:0/5-iso PGF2VI), in particular, consists of one chain of one pentadecanoyl at the C-1 position and one chain of 5-iso Prostaglandin F2alpha-VI at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PEs can be synthesized via three different routes. In one route, the oxidized PE is synthetized de novo following the same mechanisms as for PEs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PE backbone, mainly through the action of LOX (PMID: 33329396).
PE(5-iso PGF2VI/15:0)
PE(5-iso PGF2VI/15:0) is an oxidized phosphatidylethanolamine (PE). Oxidized phosphatidylethanolamines are glycerophospholipids in which a phosphorylethanolamine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylethanolamines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylethanolamines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PE(5-iso PGF2VI/15:0), in particular, consists of one chain of one 5-iso Prostaglandin F2alpha-VI at the C-1 position and one chain of pentadecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PEs can be synthesized via three different routes. In one route, the oxidized PE is synthetized de novo following the same mechanisms as for PEs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PE backbone, mainly through the action of LOX (PMID: 33329396).
PE(16:1(9Z)/18:1(12Z)-2OH(9,10))
PE(16:1(9Z)/18:1(12Z)-2OH(9,10)) is an oxidized phosphatidylethanolamine (PE). Oxidized phosphatidylethanolamines are glycerophospholipids in which a phosphorylethanolamine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylethanolamines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylethanolamines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PE(16:1(9Z)/18:1(12Z)-2OH(9,10)), in particular, consists of one chain of one 9Z-hexadecenoyl at the C-1 position and one chain of 9,10-hydroxy-octadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PEs can be synthesized via three different routes. In one route, the oxidized PE is synthetized de novo following the same mechanisms as for PEs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PE backbone, mainly through the action of LOX (PMID: 33329396).
PE(18:1(12Z)-2OH(9,10)/16:1(9Z))
PE(18:1(12Z)-2OH(9,10)/16:1(9Z)) is an oxidized phosphatidylethanolamine (PE). Oxidized phosphatidylethanolamines are glycerophospholipids in which a phosphorylethanolamine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylethanolamines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylethanolamines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PE(18:1(12Z)-2OH(9,10)/16:1(9Z)), in particular, consists of one chain of one 9,10-hydroxy-octadecenoyl at the C-1 position and one chain of 9Z-hexadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PEs can be synthesized via three different routes. In one route, the oxidized PE is synthetized de novo following the same mechanisms as for PEs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PE backbone, mainly through the action of LOX (PMID: 33329396).
PS(14:0/18:1(12Z)-O(9S,10R))
PS(14:0/18:1(12Z)-O(9S,10R)) is an oxidized phosphatidylserine (PS). Oxidized phosphatidylserines are glycerophospholipids in which a phosphorylserine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylserines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylserines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PS(14:0/18:1(12Z)-O(9S,10R)), in particular, consists of one chain of one tetradecanoyl at the C-1 position and one chain of 9,10-epoxy-octadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PSs can be synthesized via three different routes. In one route, the oxidized PS is synthetized de novo following the same mechanisms as for PSs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PS backbone, mainly through the action of LOX (PMID: 33329396).
PS(18:1(12Z)-O(9S,10R)/14:0)
PS(18:1(12Z)-O(9S,10R)/14:0) is an oxidized phosphatidylserine (PS). Oxidized phosphatidylserines are glycerophospholipids in which a phosphorylserine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylserines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylserines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PS(18:1(12Z)-O(9S,10R)/14:0), in particular, consists of one chain of one 9,10-epoxy-octadecenoyl at the C-1 position and one chain of tetradecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PSs can be synthesized via three different routes. In one route, the oxidized PS is synthetized de novo following the same mechanisms as for PSs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PS backbone, mainly through the action of LOX (PMID: 33329396).
PS(14:0/18:1(9Z)-O(12,13))
PS(14:0/18:1(9Z)-O(12,13)) is an oxidized phosphatidylserine (PS). Oxidized phosphatidylserines are glycerophospholipids in which a phosphorylserine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylserines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylserines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PS(14:0/18:1(9Z)-O(12,13)), in particular, consists of one chain of one tetradecanoyl at the C-1 position and one chain of 12,13-epoxy-octadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PSs can be synthesized via three different routes. In one route, the oxidized PS is synthetized de novo following the same mechanisms as for PSs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PS backbone, mainly through the action of LOX (PMID: 33329396).
PS(18:1(9Z)-O(12,13)/14:0)
PS(18:1(9Z)-O(12,13)/14:0) is an oxidized phosphatidylserine (PS). Oxidized phosphatidylserines are glycerophospholipids in which a phosphorylserine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylserines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylserines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PS(18:1(9Z)-O(12,13)/14:0), in particular, consists of one chain of one 12,13-epoxy-octadecenoyl at the C-1 position and one chain of tetradecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PSs can be synthesized via three different routes. In one route, the oxidized PS is synthetized de novo following the same mechanisms as for PSs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PS backbone, mainly through the action of LOX (PMID: 33329396).
Clarithromycin
The 6-O-methyl ether of erythromycin A, clarithromycin is a macrolide antibiotic used in the treatment of respiratory-tract, skin and soft-tissue infections. It is also used to eradicate Helicobacter pylori in the treatment of peptic ulcer disease. It prevents bacteria from growing by interfering with their protein synthesis. J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01F - Macrolides, lincosamides and streptogramins > J01FA - Macrolides D004791 - Enzyme Inhibitors > D065607 - Cytochrome P-450 Enzyme Inhibitors > D065692 - Cytochrome P-450 CYP3A Inhibitors COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D004791 - Enzyme Inhibitors > D011500 - Protein Synthesis Inhibitors D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents C784 - Protein Synthesis Inhibitor > C261 - Macrolide Antibiotic C254 - Anti-Infective Agent > C258 - Antibiotic Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Origin: Microbe CONFIDENCE standard compound; INTERNAL_ID 1053 CONFIDENCE standard compound; INTERNAL_ID 4085
Phosphatidylethanolamine alkenyl 16:0-22:6
C43H74NO7P (747.5202623999999)
(2-aminoethoxy)[2-[docosa-4.7.10.13.16.19-hexaenoyloxy]-3-[hexadec-1-en-1-yloxy]propoxy]phosphinic acid
C43H74NO7P (747.5202623999999)
PE(P-16:0/22:6)
C43H74NO7P (747.5202623999999)
PE(38:6)
C43H74NO7P (747.5202623999999)
PE(P-18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))
C43H74NO7P (747.5202623999999)
PE(15:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
PE(17:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))
PE(20:5(5Z,8Z,11Z,14Z,17Z)/17:2(9Z,12Z))
PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/15:1(9Z))
PS(O-20:0/14:1(9Z))
C40H78NO9P (747.5413907999999)
PS(O-18:0/16:1(9Z))
C40H78NO9P (747.5413907999999)
PS(O-16:0/18:1(9Z))
C40H78NO9P (747.5413907999999)
PS(P-16:0/18:0)
C40H78NO9P (747.5413907999999)
PS(P-18:0/16:0)
C40H78NO9P (747.5413907999999)
PS(P-20:0/14:0)
C40H78NO9P (747.5413907999999)
PE 37:7
PE O-38:7
C43H74NO7P (747.5202623999999)
1-[(9Z)-octadec-9-enoyl]-2-hexadecanoyl-sn-glycero-3-phospho-(1-sn-glycerol)(1-)
A 1,2-diacyl-sn-glycero-3-phospho-(1-sn-glycerol)(1-) in which the 1- and 2-acyl groups are specified as (9Z)-octadec-9-enoyl (oleoyl) and hexadecanoyl (palmitoyl) respectively; major species at pH 7.3.
Phosphatidylglycerol (1-palmitoyl, 2-cis-vaccenoyl)
(2S)-2-amino-3-[hydroxy-[(2R)-2-[(Z)-11-(3-pentyloxiran-2-yl)undec-9-enoyl]oxy-3-tetradecanoyloxypropoxy]phosphoryl]oxypropanoic acid
(2S)-2-amino-3-[hydroxy-[(2R)-3-[(Z)-11-(3-pentyloxiran-2-yl)undec-9-enoyl]oxy-2-tetradecanoyloxypropoxy]phosphoryl]oxypropanoic acid
2-amino-3-[hydroxy-[3-icosoxy-2-[(E)-tetradec-9-enoyl]oxypropoxy]phosphoryl]oxypropanoic acid
C40H78NO9P (747.5413907999999)
2-azaniumylethyl (2R)-2-{[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]oxy}-3-{[(1Z)-hexadec-1-en-1-yl]oxy}propyl phosphate
C43H74NO7P (747.5202623999999)
1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol(1-)
A phosphatidylglycerol(1-) that is the conjugate base of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol obtained by deprotonation of the phosphate OH group; major species at pH 7.3.
1-Palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1-sn-glycerol)(1-)
A 1,2-diacyl-sn-glycero-3-phospho-(1-sn-glycerol)(1-) in which the 1- and 2-acyl groups are specified as hexadecanoyl (palmitoyl) and 9Z-octadecenoyl (oleoyl) respectively; major species at pH 7.3.
11-(4-dimethylamino-3-hydroxy-6-methyltetrahydro-2H-2-pyranyloxy)-3-ethyl-4,5-dihydroxy-13-(5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-2-pyranyloxy)-10-methoxy-4,6,8,10,12,14-hexamethyl-2-oxacyclotetradecane-1,7-dione
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-hexadec-9-enoxy]propan-2-yl] (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate
C43H74NO7P (747.5202623999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoxy]propan-2-yl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate
C43H74NO7P (747.5202623999999)
[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (17Z,20Z,23Z,26Z,29Z,32Z,35Z)-octatriaconta-17,20,23,26,29,32,35-heptaenoate
C43H74NO7P (747.5202623999999)
[2-[(5Z,8Z,11Z,14Z,17Z,20Z,23Z)-hexacosa-5,8,11,14,17,20,23-heptaenoyl]oxy-3-nonoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C43H74NO7P (747.5202623999999)
[2-heptanoyloxy-3-[(7Z,10Z,13Z,16Z,19Z,22Z,25Z)-octacosa-7,10,13,16,19,22,25-heptaenoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
C43H74NO7P (747.5202623999999)
[3-[(5Z,8Z,11Z,14Z,17Z,20Z,23Z)-hexacosa-5,8,11,14,17,20,23-heptaenoxy]-2-nonanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C43H74NO7P (747.5202623999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoxy]propan-2-yl] (10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoate
C43H74NO7P (747.5202623999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(11Z,14Z)-icosa-11,14-dienoxy]propan-2-yl] (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate
C43H74NO7P (747.5202623999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(5Z,8Z,11Z,14Z,17Z,20Z,23Z)-hexacosa-5,8,11,14,17,20,23-heptaenoxy]propan-2-yl] dodecanoate
C43H74NO7P (747.5202623999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-decoxypropan-2-yl] (7Z,10Z,13Z,16Z,19Z,22Z,25Z)-octacosa-7,10,13,16,19,22,25-heptaenoate
C43H74NO7P (747.5202623999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(6Z,9Z,12Z,15Z,18Z,21Z)-tetracosa-6,9,12,15,18,21-hexaenoxy]propan-2-yl] (Z)-tetradec-9-enoate
C43H74NO7P (747.5202623999999)
(2S)-2-amino-3-[[(2R)-2-[(Z)-16,16,17,17,18,18,18-heptadeuteriooctadec-9-enoyl]oxy-3-pentadecanoyloxypropoxy]-hydroxyphosphoryl]oxypropanoic acid
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoxy]propan-2-yl] (10Z,13Z,16Z)-docosa-10,13,16-trienoate
C43H74NO7P (747.5202623999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tetradec-9-enoxy]propan-2-yl] (6Z,9Z,12Z,15Z,18Z,21Z)-tetracosa-6,9,12,15,18,21-hexaenoate
C43H74NO7P (747.5202623999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-dodecoxypropan-2-yl] (5Z,8Z,11Z,14Z,17Z,20Z,23Z)-hexacosa-5,8,11,14,17,20,23-heptaenoate
C43H74NO7P (747.5202623999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(7Z,10Z,13Z,16Z,19Z,22Z,25Z)-octacosa-7,10,13,16,19,22,25-heptaenoxy]propan-2-yl] decanoate
C43H74NO7P (747.5202623999999)
2-amino-3-[[3-henicosoxy-2-[(Z)-tridec-9-enoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid
C40H78NO9P (747.5413907999999)
2-amino-3-[[3-[(Z)-hexadec-9-enoxy]-2-octadecanoyloxypropoxy]-hydroxyphosphoryl]oxypropanoic acid
C40H78NO9P (747.5413907999999)
2-amino-3-[hydroxy-[3-[(Z)-nonadec-9-enoxy]-2-pentadecanoyloxypropoxy]phosphoryl]oxypropanoic acid
C40H78NO9P (747.5413907999999)
2-amino-3-[[3-decoxy-2-[(Z)-tetracos-13-enoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid
C40H78NO9P (747.5413907999999)
2-amino-3-[[2-[(Z)-heptadec-9-enoyl]oxy-3-heptadecoxypropoxy]-hydroxyphosphoryl]oxypropanoic acid
C40H78NO9P (747.5413907999999)
2-amino-3-[[2-hexadecanoyloxy-3-[(Z)-octadec-9-enoxy]propoxy]-hydroxyphosphoryl]oxypropanoic acid
C40H78NO9P (747.5413907999999)
2-amino-3-[hydroxy-[3-icosoxy-2-[(Z)-tetradec-9-enoyl]oxypropoxy]phosphoryl]oxypropanoic acid
C40H78NO9P (747.5413907999999)
2-amino-3-[[2-[(Z)-hexadec-9-enoyl]oxy-3-octadecoxypropoxy]-hydroxyphosphoryl]oxypropanoic acid
C40H78NO9P (747.5413907999999)
2-amino-3-[[2-[(Z)-henicos-11-enoyl]oxy-3-tridecoxypropoxy]-hydroxyphosphoryl]oxypropanoic acid
C40H78NO9P (747.5413907999999)
[3-[(9Z,12Z)-heptadeca-9,12-dienoxy]-2-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C43H74NO7P (747.5202623999999)
2-amino-3-[hydroxy-[2-[(Z)-icos-11-enoyl]oxy-3-tetradecoxypropoxy]phosphoryl]oxypropanoic acid
C40H78NO9P (747.5413907999999)
2-amino-3-[[2-[(Z)-docos-13-enoyl]oxy-3-dodecoxypropoxy]-hydroxyphosphoryl]oxypropanoic acid
C40H78NO9P (747.5413907999999)
2-amino-3-[hydroxy-[3-nonadecoxy-2-[(Z)-pentadec-9-enoyl]oxypropoxy]phosphoryl]oxypropanoic acid
C40H78NO9P (747.5413907999999)
[2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]oxy-3-[(Z)-tridec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
C43H74NO7P (747.5202623999999)
2-amino-3-[[3-hexadecoxy-2-[(Z)-octadec-9-enoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid
C40H78NO9P (747.5413907999999)
2-amino-3-[hydroxy-[2-[(Z)-nonadec-9-enoyl]oxy-3-pentadecoxypropoxy]phosphoryl]oxypropanoic acid
C40H78NO9P (747.5413907999999)
2-amino-3-[hydroxy-[2-icosanoyloxy-3-[(Z)-tetradec-9-enoxy]propoxy]phosphoryl]oxypropanoic acid
C40H78NO9P (747.5413907999999)
2-amino-3-[hydroxy-[3-[(Z)-icos-11-enoxy]-2-tetradecanoyloxypropoxy]phosphoryl]oxypropanoic acid
C40H78NO9P (747.5413907999999)
2-amino-3-[hydroxy-[2-nonadecanoyloxy-3-[(Z)-pentadec-9-enoxy]propoxy]phosphoryl]oxypropanoic acid
C40H78NO9P (747.5413907999999)
2-amino-3-[[2-decanoyloxy-3-[(Z)-tetracos-13-enoxy]propoxy]-hydroxyphosphoryl]oxypropanoic acid
C40H78NO9P (747.5413907999999)
2-amino-3-[[2-henicosanoyloxy-3-[(Z)-tridec-9-enoxy]propoxy]-hydroxyphosphoryl]oxypropanoic acid
C40H78NO9P (747.5413907999999)
2-amino-3-[[3-[(Z)-henicos-11-enoxy]-2-tridecanoyloxypropoxy]-hydroxyphosphoryl]oxypropanoic acid
C40H78NO9P (747.5413907999999)
2-amino-3-[[3-[(Z)-docos-13-enoxy]-2-dodecanoyloxypropoxy]-hydroxyphosphoryl]oxypropanoic acid
C40H78NO9P (747.5413907999999)
2-amino-3-[[2-heptadecanoyloxy-3-[(Z)-heptadec-9-enoxy]propoxy]-hydroxyphosphoryl]oxypropanoic acid
C40H78NO9P (747.5413907999999)
2-[4-[10,13-dimethyl-3-[(Z)-octadec-9-enoyl]oxy-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoylamino]ethanesulfonic acid
C44H77NO6S (747.5471302000001)
2-[4-[3-[(9Z,12Z)-heptadeca-9,12-dienoyl]oxy-12-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoylamino]ethanesulfonic acid
C43H73NO7S (747.5107467999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-undecanoyloxypropan-2-yl] (5Z,8Z,11Z,14Z,17Z,20Z,23Z)-hexacosa-5,8,11,14,17,20,23-heptaenoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tridec-9-enoyl]oxypropan-2-yl] (6Z,9Z,12Z,15Z,18Z,21Z)-tetracosa-6,9,12,15,18,21-hexaenoate
(3R,7R,11R,12R,13S)-6-[4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-12,13-dihydroxy-4-(5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl)oxy-7-methoxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione
4-[2,3-bis[[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]oxy]propoxy]-2-(trimethylazaniumyl)butanoate
(2S)-2-amino-3-[hydroxy-[(2R)-1,1,2,3,3-pentadeuterio-3-heptadecanoyloxy-2-[(Z)-hexadec-9-enoyl]oxypropoxy]phosphoryl]oxypropanoic acid
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoxy]propan-2-yl] (11Z,14Z)-icosa-11,14-dienoate
C43H74NO7P (747.5202623999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoxy]propan-2-yl] (9Z,12Z)-hexadeca-9,12-dienoate
C43H74NO7P (747.5202623999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoxy]propan-2-yl] (11Z,14Z,17Z)-icosa-11,14,17-trienoate
C43H74NO7P (747.5202623999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoxy]propan-2-yl] (Z)-hexadec-9-enoate
C43H74NO7P (747.5202623999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-octadeca-9,12-dienoxy]propan-2-yl] (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate
C43H74NO7P (747.5202623999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoxy]propan-2-yl] (9Z,12Z)-octadeca-9,12-dienoate
C43H74NO7P (747.5202623999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoxy]propan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate
C43H74NO7P (747.5202623999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-hexadeca-9,12-dienoxy]propan-2-yl] (7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoate
C43H74NO7P (747.5202623999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoxy]propan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate
C43H74NO7P (747.5202623999999)
[2-[(9Z,12Z)-heptadeca-9,12-dienoyl]oxy-3-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
C43H74NO7P (747.5202623999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(10Z,13Z,16Z)-docosa-10,13,16-trienoxy]propan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate
C43H74NO7P (747.5202623999999)
[3-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoxy]-2-[(Z)-tridec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C43H74NO7P (747.5202623999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(11Z,14Z,17Z)-icosa-11,14,17-trienoxy]propan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate
C43H74NO7P (747.5202623999999)
2-amino-3-[hydroxy-[3-nonanoyloxy-2-[(Z)-tetracos-13-enoyl]oxypropoxy]phosphoryl]oxypropanoic acid
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-nonanoyloxypropan-2-yl] (7Z,10Z,13Z,16Z,19Z,22Z,25Z)-octacosa-7,10,13,16,19,22,25-heptaenoate
[2-[(5Z,8Z,11Z,14Z,17Z,20Z,23Z)-hexacosa-5,8,11,14,17,20,23-heptaenoyl]oxy-3-octanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
2-amino-3-[hydroxy-[3-octadecanoyloxy-2-[(Z)-pentadec-9-enoyl]oxypropoxy]phosphoryl]oxypropanoic acid
2-amino-3-[[2-[(Z)-docos-13-enoyl]oxy-3-undecanoyloxypropoxy]-hydroxyphosphoryl]oxypropanoic acid
2-amino-3-[hydroxy-[2-[(Z)-nonadec-9-enoyl]oxy-3-tetradecanoyloxypropoxy]phosphoryl]oxypropanoic acid
2-amino-3-[[2-[(Z)-heptadec-9-enoyl]oxy-3-hexadecanoyloxypropoxy]-hydroxyphosphoryl]oxypropanoic acid
[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]oxypropyl] (9Z,12Z)-nonadeca-9,12-dienoate
2-amino-3-[[3-dodecanoyloxy-2-[(Z)-henicos-11-enoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid
2-amino-3-[hydroxy-[2-[(Z)-icos-11-enoyl]oxy-3-tridecanoyloxypropoxy]phosphoryl]oxypropanoic acid
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-heptadeca-9,12-dienoyl]oxypropan-2-yl] (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-pentadec-9-enoyl]oxypropan-2-yl] (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate
2-amino-3-[hydroxy-[2-[(Z)-octadec-9-enoyl]oxy-3-pentadecanoyloxypropoxy]phosphoryl]oxypropanoic acid
2-amino-3-[[3-heptadecanoyloxy-2-[(Z)-hexadec-9-enoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid
2-amino-3-[hydroxy-[3-nonadecanoyloxy-2-[(Z)-tetradec-9-enoyl]oxypropoxy]phosphoryl]oxypropanoic acid
2-amino-3-[hydroxy-[3-icosanoyloxy-2-[(Z)-tridec-9-enoyl]oxypropoxy]phosphoryl]oxypropanoic acid
[3-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxy-2-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
2-amino-3-[[3-heptanoyloxy-2-[(Z)-hexacos-15-enoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid
[3-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxy-2-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
N-[(4E,8E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxyhenicosa-4,8-dien-2-yl]pentanamide
N-[(4E,8E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxydodeca-4,8-dien-2-yl]tetradecanamide
(9Z,12Z)-N-[1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxynonan-2-yl]heptadeca-9,12-dienamide
N-[(4E,8E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxyicosa-4,8-dien-2-yl]hexanamide
N-[(4E,8E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxytrideca-4,8-dien-2-yl]tridecanamide
N-[(4E,8E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxytricosa-4,8-dien-2-yl]propanamide
(9Z,12Z)-N-[1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxyoctan-2-yl]octadeca-9,12-dienamide
(Z)-N-[(E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxytridec-4-en-2-yl]tridec-9-enamide
(Z)-N-[(E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxydodec-4-en-2-yl]tetradec-9-enamide
N-[(4E,8E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxytetradeca-4,8-dien-2-yl]dodecanamide
(9Z,12Z)-N-[1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxydecan-2-yl]hexadeca-9,12-dienamide
N-[(4E,8E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxytetracosa-4,8-dien-2-yl]acetamide
N-[(4E,8E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxydocosa-4,8-dien-2-yl]butanamide
(Z)-N-[(E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxynon-4-en-2-yl]heptadec-9-enamide
N-[(4E,8E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxynonadeca-4,8-dien-2-yl]heptanamide
(Z)-N-[(E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxyoct-4-en-2-yl]octadec-9-enamide
(Z)-N-[(E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxyundec-4-en-2-yl]pentadec-9-enamide
N-[(4E,8E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxyhexadeca-4,8-dien-2-yl]decanamide
(Z)-N-[(E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxydec-4-en-2-yl]hexadec-9-enamide
N-[(4E,8E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxypentadeca-4,8-dien-2-yl]undecanamide
N-[(4E,8E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxyoctadeca-4,8-dien-2-yl]octanamide
N-[(4E,8E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxyheptadeca-4,8-dien-2-yl]nonanamide
4-[2-[(7E,9E,11E,13E,15E,17E,19E)-docosa-7,9,11,13,15,17,19-heptaenoyl]oxy-3-[(5E,8E,11E)-tetradeca-5,8,11-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
[(2R)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-[(9E,12E)-heptadeca-9,12-dienoyl]oxypropyl] (5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoate
(2S)-2-amino-3-[hydroxy-[(2R)-3-octadecanoyloxy-2-[(E)-pentadec-9-enoyl]oxypropoxy]phosphoryl]oxypropanoic acid
(2S)-2-amino-3-[[(2S)-2-[(E)-docos-13-enoyl]oxy-3-undecanoyloxypropoxy]-hydroxyphosphoryl]oxypropanoic acid
[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxypropyl] (9E,11E)-henicosa-9,11-dienoate
[(2S)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-[(E)-pentadec-9-enoyl]oxypropyl] (4E,7E,10E,13E,16E,19E)-docosa-4,7,10,13,16,19-hexaenoate
(2S)-2-amino-3-[hydroxy-[(2R)-2-octadecanoyloxy-3-[(E)-pentadec-9-enoyl]oxypropoxy]phosphoryl]oxypropanoic acid
(2S)-2-amino-3-[[(2R)-2-[(E)-heptadec-9-enoyl]oxy-3-hexadecanoyloxypropoxy]-hydroxyphosphoryl]oxypropanoic acid
(2S)-2-amino-3-[hydroxy-[(2R)-2-nonadecanoyloxy-3-[(E)-tetradec-9-enoyl]oxypropoxy]phosphoryl]oxypropanoic acid
(2S)-2-amino-3-[hydroxy-[(2R)-3-[(E)-octadec-9-enoyl]oxy-2-pentadecanoyloxypropoxy]phosphoryl]oxypropanoic acid
(2S)-2-amino-3-[hydroxy-[(2R)-3-[(E)-octadec-13-enoyl]oxy-2-pentadecanoyloxypropoxy]phosphoryl]oxypropanoic acid
[2-[(4E,7E)-hexadeca-4,7-dienoyl]oxy-3-[(7E,9E,11E,13E,15E)-octadeca-7,9,11,13,15-pentaenoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
(2S)-2-amino-3-[[(2R)-2-heptadecanoyloxy-3-[(E)-hexadec-9-enoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid
4-[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-[(5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
(2S)-2-amino-3-[hydroxy-[(2R)-2-[(E)-octadec-13-enoyl]oxy-3-pentadecanoyloxypropoxy]phosphoryl]oxypropanoic acid
4-[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-[(7E,9E,11E,13E,15E,17E)-icosa-7,9,11,13,15,17-hexaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
(2S)-2-amino-3-[hydroxy-[(2S)-2-[(E)-icos-11-enoyl]oxy-3-tridecanoyloxypropoxy]phosphoryl]oxypropanoic acid
4-[3-[(7E,9E,11E,13E,15E,17E,19E)-docosa-7,9,11,13,15,17,19-heptaenoyl]oxy-2-[(5E,8E,11E)-tetradeca-5,8,11-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
(2R)-2-amino-3-[[(2S)-3-[(E)-docos-13-enoyl]oxy-2-undecanoyloxypropoxy]-hydroxyphosphoryl]oxypropanoic acid
(2S)-2-amino-3-[[(2R)-3-[(E)-heptadec-9-enoyl]oxy-2-hexadecanoyloxypropoxy]-hydroxyphosphoryl]oxypropanoic acid
[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9E,12E)-heptadeca-9,12-dienoyl]oxypropan-2-yl] (5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoate
[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(E)-pentadec-9-enoyl]oxypropan-2-yl] (4E,7E,10E,13E,16E,19E)-docosa-4,7,10,13,16,19-hexaenoate
(2S)-2-amino-3-[hydroxy-[(2R)-3-[(E)-octadec-4-enoyl]oxy-2-pentadecanoyloxypropoxy]phosphoryl]oxypropanoic acid
(2S)-2-amino-3-[hydroxy-[(2R)-2-[(E)-octadec-9-enoyl]oxy-3-pentadecanoyloxypropoxy]phosphoryl]oxypropanoic acid
[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxypropyl] (9E,11E,13E)-henicosa-9,11,13-trienoate
4-[2,3-bis[[(7E,9E,11E,13E,15E)-octadeca-7,9,11,13,15-pentaenoyl]oxy]propoxy]-2-(trimethylazaniumyl)butanoate
(2S)-2-amino-3-[hydroxy-[(2R)-2-octadec-17-enoyloxy-3-pentadecanoyloxypropoxy]phosphoryl]oxypropanoic acid
(2S)-2-amino-3-[hydroxy-[(2S)-2-[(E)-icos-13-enoyl]oxy-3-tridecanoyloxypropoxy]phosphoryl]oxypropanoic acid
(2S)-2-amino-3-[[(2R)-2-heptadecanoyloxy-3-[(E)-hexadec-7-enoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid
(2S)-2-amino-3-[[(2R)-3-heptadecanoyloxy-2-[(E)-hexadec-7-enoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid
(2S)-2-amino-3-[hydroxy-[(2R)-3-[(E)-octadec-11-enoyl]oxy-2-pentadecanoyloxypropoxy]phosphoryl]oxypropanoic acid
(2S)-2-amino-3-[[(2R)-3-heptadecanoyloxy-2-[(E)-hexadec-9-enoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid
[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxypropyl] (9E,11E,13E,15E)-henicosa-9,11,13,15-tetraenoate
(2S)-2-amino-3-[hydroxy-[(2R)-2-[(E)-octadec-6-enoyl]oxy-3-pentadecanoyloxypropoxy]phosphoryl]oxypropanoic acid
(2R)-2-amino-3-[hydroxy-[(2S)-3-[(E)-icos-11-enoyl]oxy-2-tridecanoyloxypropoxy]phosphoryl]oxypropanoic acid
(2S)-2-amino-3-[hydroxy-[(2R)-3-[(E)-octadec-7-enoyl]oxy-2-pentadecanoyloxypropoxy]phosphoryl]oxypropanoic acid
(2S)-2-amino-3-[hydroxy-[(2R)-3-[(E)-octadec-6-enoyl]oxy-2-pentadecanoyloxypropoxy]phosphoryl]oxypropanoic acid
[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-[(4E,7E)-hexadeca-4,7-dienoyl]oxypropyl] (9E,11E,13E,15E,17E)-henicosa-9,11,13,15,17-pentaenoate
4-[3-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-2-[(5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
(2S)-2-amino-3-[hydroxy-[(2R)-2-[(E)-octadec-4-enoyl]oxy-3-pentadecanoyloxypropoxy]phosphoryl]oxypropanoic acid
(2S)-2-amino-3-[hydroxy-[(2R)-3-octadec-17-enoyloxy-2-pentadecanoyloxypropoxy]phosphoryl]oxypropanoic acid
4-[3-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-2-[(7E,9E,11E,13E,15E,17E)-icosa-7,9,11,13,15,17-hexaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
(2R)-2-amino-3-[hydroxy-[(2S)-3-nonadecanoyloxy-2-[(E)-tetradec-9-enoyl]oxypropoxy]phosphoryl]oxypropanoic acid
(2R)-2-amino-3-[hydroxy-[(2S)-3-[(E)-icos-13-enoyl]oxy-2-tridecanoyloxypropoxy]phosphoryl]oxypropanoic acid
[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-[(10E,12E)-octadeca-10,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
(2S)-2-amino-3-[hydroxy-[(2R)-2-[(E)-octadec-7-enoyl]oxy-3-pentadecanoyloxypropoxy]phosphoryl]oxypropanoic acid
[2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-3-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-[(11E,13E,15E)-octadeca-11,13,15-trienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
(2S)-2-amino-3-[hydroxy-[(2R)-2-[(E)-octadec-11-enoyl]oxy-3-pentadecanoyloxypropoxy]phosphoryl]oxypropanoic acid
2-[hydroxy-[3-hydroxy-2-[[(9Z,12Z,15Z,18Z,21Z,24Z,27Z)-triaconta-9,12,15,18,21,24,27-heptaenoyl]amino]octoxy]phosphoryl]oxyethyl-trimethylazanium
C43H76N2O6P+ (747.5440705999999)
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-[[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoyl]amino]octadeca-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
C43H76N2O6P+ (747.5440705999999)
2-[[2-[[(5Z,8Z,11Z,14Z,17Z,20Z,23Z)-hexacosa-5,8,11,14,17,20,23-heptaenoyl]amino]-3-hydroxydodecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C43H76N2O6P+ (747.5440705999999)
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-[[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]amino]icosa-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
C43H76N2O6P+ (747.5440705999999)
2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]amino]icosa-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
C43H76N2O6P+ (747.5440705999999)
2-[hydroxy-[(E)-3-hydroxy-2-[[(10Z,13Z,16Z,19Z,22Z,25Z)-octacosa-10,13,16,19,22,25-hexaenoyl]amino]dec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C43H76N2O6P+ (747.5440705999999)
2-[[(4E,8E)-2-[[(11Z,14Z,17Z,20Z,23Z)-hexacosa-11,14,17,20,23-pentaenoyl]amino]-3-hydroxydodeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C43H76N2O6P+ (747.5440705999999)
2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(9Z,12Z,15Z,18Z,21Z)-tetracosa-9,12,15,18,21-pentaenoyl]amino]tetradeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
C43H76N2O6P+ (747.5440705999999)
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-[[(12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoyl]amino]tetradeca-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
C43H76N2O6P+ (747.5440705999999)
2-[hydroxy-[3-hydroxy-2-[[(7Z,10Z,13Z,16Z,19Z,22Z,25Z)-octacosa-7,10,13,16,19,22,25-heptaenoyl]amino]decoxy]phosphoryl]oxyethyl-trimethylazanium
C43H76N2O6P+ (747.5440705999999)
2-[hydroxy-[(E)-3-hydroxy-2-[[(12Z,15Z,18Z,21Z,24Z,27Z)-triaconta-12,15,18,21,24,27-hexaenoyl]amino]oct-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C43H76N2O6P+ (747.5440705999999)
2-[[(E)-2-[[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]amino]-3-hydroxyhexadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C43H76N2O6P+ (747.5440705999999)
2-[[(4E,8E,12E)-2-[[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]amino]-3-hydroxydocosa-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C43H76N2O6P+ (747.5440705999999)
2-[hydroxy-[(E)-3-hydroxy-2-[[(6Z,9Z,12Z,15Z,18Z,21Z)-tetracosa-6,9,12,15,18,21-hexaenoyl]amino]tetradec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C43H76N2O6P+ (747.5440705999999)
2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyl]amino]octadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
C43H76N2O6P+ (747.5440705999999)
2-[[(E)-2-[[(8Z,11Z,14Z,17Z,20Z,23Z)-hexacosa-8,11,14,17,20,23-hexaenoyl]amino]-3-hydroxydodec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C43H76N2O6P+ (747.5440705999999)
2-[[(4E,8E)-2-[[(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoyl]amino]-3-hydroxyhexadeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C43H76N2O6P+ (747.5440705999999)
2-[[(4E,8E,12E)-2-[[(10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoyl]amino]-3-hydroxyhexadeca-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C43H76N2O6P+ (747.5440705999999)
1-(1Z-hexadecenyl)-2-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-glycero-3-phosphoethanolamine
C43H74NO7P (747.5202623999999)
A 1-(alk-1-enyl)-2-acyl-sn-glycero-3-phosphoethanolamine in which the alkyl and the acyl groups at positions 1 and 2 are specified as (1Z)-hexadecenyl and (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl respectively.
PE(P-18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))
C43H74NO7P (747.5202623999999)
PE(20:5(5Z,8Z,11Z,14Z,17Z)/P-18:1(11Z))
C43H74NO7P (747.5202623999999)
PE(20:5(5Z,8Z,11Z,14Z,17Z)/P-18:1(9Z))
C43H74NO7P (747.5202623999999)
phosphatidylcholine 34:7
A 1,2-diacyl-sn-glycero-3-phosphocholine in which the two acyl groups contain a total of 34 carbons and 7 double bonds.
phosphatidylethanolamine 37:7 zwitterion
A 1,2-diacyl-sn-glycero-3-phosphoethanolamine zwitterion in which the two acyl groups contain 37 carbons in total with 7 double bonds.
phosphatidylethanolamine 38:7
C43H74NO7P (747.5202623999999)
A phosphatidylethanolamine in which the two acyl groups contain a total of 38 carbons and 7 double bonds.
1-(1Z-hexadecenyl)-2-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-glycero-3-phosphoethanolamine zwitterion
C43H74NO7P (747.5202623999999)
A 1-(Z)-alk-1-enyl-2-acyl-sn-glycero-3-phosphoethanolamine zwitterion in which the alk-1-enyl and acyl groups are specified as (1Z)-hexadecenyl and (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl respectively.
PC(34:7)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
MePC(34:7)
C43H74NO7P (747.5202623999999)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
MePC(33:7)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
Hex1Cer(37:6)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
(2s)-n-[(2s,3r)-3-(acetyloxy)-2-{[(2s)-1-[(2s,4s)-4-hydroxy-2-[(2s)-2-methyl-5-oxo-2h-pyrrole-1-carbonyl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl](methyl)amino}butanoyl]-4-methyl-2-[(2r,4r)-n,2,4-trimethyloctanamido]pentanimidic acid
(25ξ)-solanidan-3β,23β-dihydroxy3-o-β-d-glucopyranosyl(1→2)-[β-d-xylopy-ranosyl(1→3)]-β-d-glucopyranosyl(1→4)-β-d-galactopyranoside
{"Ingredient_id": "HBIN004812","Ingredient_name": "(25\u03be)-solanidan-3\u03b2,23\u03b2-dihydroxy3-o-\u03b2-d-glucopyranosyl(1\u21922)-[\u03b2-d-xylopy-ranosyl(1\u21923)]-\u03b2-d-glucopyranosyl(1\u21924)-\u03b2-d-galactopyranoside","Alias": "NA","Ingredient_formula": "C41H65NO11","Ingredient_Smile": "CCC1CCCC(C(C(=O)C2=CC3C4CC(CC4C5C(C3C2CC(=O)O1)O5)OC6C(C(C(C(O6)C)OC)OC)OC)C)OC7CCC(C(O7)C)N(C)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "20037","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}